Regeneron Pharmaceuticals, Inc. (BMV:REGN)

Market Cap	1.38T -6.4%
Revenue (ttm)	258.22B +1.0%
Net Income	81.10B +2.1%
EPS	746.77 +8.2%
Shares Out	n/a
PE Ratio	16.97
Forward PE	16.19
Dividend	67.63 (0.50%)
Ex-Dividend Date	Nov 20, 2025

Volume	23
Average Volume	310
Open	13,484
Previous Close	n/a
Day's Range	13,484 - 13,484
52-Week Range	9,420 - 15,190
Beta	n/a
RSI	63.08
Earnings Date	Jan 30, 2026

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq...

• Industry: Pharmaceutical Preparations
• Founded: 1988
• Employees: 15,410
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: REGN

Financial Performance

In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.

Financial numbers in USD